Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation
H Kodama, H Kenmotsu, T Kawabata, A Notsu… - Cancer …, 2021 - Wiley Online Library
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are
currently the primary treatment option for patients with EGFR‐mutant non‐small cell lung …
currently the primary treatment option for patients with EGFR‐mutant non‐small cell lung …
[HTML][HTML] The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a …
Y Zhang, S Miao, F Wang, W Fang, G Chen… - Journal of Thoracic …, 2017 - ncbi.nlm.nih.gov
Background The first generation epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
[HTML][HTML] Is epidermal growth factor receptor tyrosine kinase inhibitor in combination with cytotoxic chemotherapy a better treatment option for patients with EGFR …
K Takahashi, H Saito - Translational Lung Cancer Research, 2016 - ncbi.nlm.nih.gov
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) combined with
cytotoxic chemotherapy achieved a high disease control rate and favorable progression-free …
cytotoxic chemotherapy achieved a high disease control rate and favorable progression-free …
[HTML][HTML] Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang… - Annals of …, 2015 - Elsevier
Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
Afatinib in the treatment of EGFR mutation-positive NSCLC–a network meta-analysis
Objectives Epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung
cancer (NSCLC) is a specific lung cancer subtype characterized by sensitivity to treatment …
cancer (NSCLC) is a specific lung cancer subtype characterized by sensitivity to treatment …
Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: a …
G Gao, S Ren, A Li, J Xu, Q Xu, C Su… - … journal of cancer, 2012 - Wiley Online Library
Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR …
F Chen, N Chen, Y Yu, J Cui - Frontiers in Oncology, 2020 - frontiersin.org
Background: Tyrosine kinase inhibitors (TKIs) are standard treatment options for non-small
cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
Clinical outcomes in non‐small‐cell lung cancer patients with EGFR mutations: pooled analysis
L Paz‐Ares, D Soulières, I Melezínek… - Journal of cellular …, 2010 - Wiley Online Library
Introduction• Literature review‐Molecular biology of EGFR mutations‐Clinical characteristics
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …
[HTML][HTML] The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer
WS Wu, YM Chen, CM Tsai, JF Shih, YC Lee… - Journal of the Chinese …, 2013 - Elsevier
Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are
effective against tumor EGFR-mutated non-small cell lung cancer (NSCLC). Patients with the …
effective against tumor EGFR-mutated non-small cell lung cancer (NSCLC). Patients with the …
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
R Garcia-Campelo, O Arrieta, B Massuti… - Lung Cancer, 2020 - Elsevier
Objectives Progression-free survival (PFS) and response rate to epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs) varies in patients with non-small-cell lung …
receptor (EGFR) tyrosine kinase inhibitors (TKIs) varies in patients with non-small-cell lung …